A SAFE note is one of the most widely used seed financing instruments in the startup world, but the conditions that make it effective for a software company can actively disadvantage a biotech founder. Understanding the structural mechanics, and where they break down in a life sciences context, is the difference between a clean cap table at Series A and a dilution problem you can’t undo.
Definition: A SAFE note (Simple Agreement for Future Equity) is a financing instrument that gives investors the right to receive equity in a future priced round in exchange for capital today, without accruing interest or having a maturity date. This makes it popular for early-stage startups but structurally complex for biotech companies with long development timelines and milestone-driven valuation events.
What a SAFE Note Actually Is — and What It Is Not
Y Combinator introduced the SAFE in 2013 as a faster, cheaper alternative to convertible notes for early-stage tech startups. The core mechanism is straightforward: an investor provides capital today in exchange for the contractual right to convert that investment into equity when a future priced equity round occurs, at either a discounted price or a capped valuation — whichever is more favorable to the investor.
The key structural distinction from a convertible note is that a SAFE carries no debt obligation. There’s no interest rate accruing, no maturity date triggering repayment, and no legal pressure on the company to return capital if a priced round doesn’t materialize on schedule. For a SaaS startup expecting an institutional Series A within 18 months, that open-ended timeline is an asset. For a biotech company that might spend four years in preclinical development before institutional investors engage, it’s a more complicated picture.
A SAFE is not a loan. It’s not equity. It’s a contractual right that sits on the cap table as a future obligation until a qualifying conversion event occurs. That distinction matters because it affects how you model dilution, how investors perceive the instrument, and whether the conversion triggers in a standard SAFE template actually align with how your company will reach its next major financing milestone.
Key Takeaway: SAFEs carry no interest and no maturity date, which removes repayment pressure but also removes the conversion timeline certainty that some biotech investors need. The instrument was designed for tech startups with short paths to priced rounds, and that design assumption shapes every clause in the standard template.
Pre-Money vs Post-Money SAFEs: The Dilution Shift
The original Y Combinator SAFE was pre-money, meaning the valuation cap was applied before accounting for the SAFE investment itself. This created real ambiguity about how much dilution founders would face at conversion, because the calculation depended on how many other SAFEs had been issued and at what caps.
In 2018, Y Combinator revised the standard to a post-money structure. In a post-money SAFE, the valuation cap is applied after including the SAFE investment in the company’s notional value. The result is greater clarity for investors about their ownership percentage at conversion. The trade-off is that dilution risk shifts more explicitly onto founders and option pool holders. According to competitor research data, 85% of all SAFEs signed in the US are now post-money, making this the default structure you’ll encounter in practice.
Why the Post-Money Shift Matters for Biotech Founders
Post-money SAFEs give each investor a predictable ownership percentage at conversion. If you issue a $500K SAFE against a $5M post-money cap, that investor expects to own 10% of the company at the point of conversion, before any new money from the priced round dilutes them. That clarity is good for investor relations. The problem for biotech founders is that stacking multiple post-money SAFEs before a priced round means each new SAFE investor’s ownership percentage is calculated on a growing denominator, compressing founder equity in a way that’s mathematically predictable but frequently underestimated at the time of signing.
Consider a preclinical biotech that raises three SAFE rounds totaling $1.5M against a $6M post-money cap before a $10M Series A. Each SAFE investor’s conversion calculation is independent and fixed. When you add the Series A investors and the option pool expansion that institutional investors typically require, the cumulative dilution to founder equity can be severe. The math is deterministic. The mistake is not running it before you sign the first SAFE.
The Dilution Problem: How SAFE Stacking Works in Practice
Biotech companies typically require multiple pre-Series A funding rounds before institutional investors engage. Seed, pre-seed, and bridge rounds are common, and each one may involve a SAFE. This stacking pattern is where post-money dilution mechanics become material.
Research data indicates that a founder who starts with 78% ownership may find themselves owning just 35% after SAFE conversion at Series A. That compression happens through two simultaneous mechanisms: the conversion of stacked SAFEs into equity, and the creation of an option pool that institutional investors require before they price the round.
The Option Pool Double Compression
Series A investors in life sciences typically require a 15-20% option pool to be established pre-money, meaning it’s carved from founder equity before the Series A investment is priced. This option pool creation happens at the same moment as SAFE conversion. The result is a double compression that founders rarely model accurately at seed stage, because the two dilution events feel separate but land simultaneously on the cap table.
The practical tool here is a post-money dilution spreadsheet that models cap table ownership across multiple SAFE rounds, with a projected option pool expansion built in. You should run this before signing the first SAFE, not after the third. The numbers aren’t complicated — they just require you to project forward rather than calculate backward from the current round.
A Worked Example
Assume a biotech founder holds 80% of a company at pre-seed. They raise three SAFEs:
- SAFE 1: $300K at $4M post-money cap (7.5% ownership at conversion)
- SAFE 2: $500K at $5M post-money cap (10% ownership at conversion)
- SAFE 3: $700K at $6M post-money cap (11.7% ownership at conversion)
Before the Series A, SAFE investors collectively hold conversion rights to approximately 29% of the company. A 15% option pool is then created pre-money. The founder’s 80% stake, before any Series A dilution, is already compressed to around 44%. After a $10M Series A at a $20M pre-money valuation, the founder’s ownership drops further. The final number depends on exact mechanics, but the direction is clear. Stacking SAFEs without modeling the cumulative effect is one of the most common and correctable mistakes in early biotech financing.
Where SAFEs Work in Biotech — and the Conditions That Make Them Appropriate
SAFEs are well-suited to biotech companies that have a clear, near-term path to a priced institutional round, typically within 18-24 months, and are raising from angels or early-stage funds comfortable with the instrument. Platform biotech companies with strong IP positions can use SAFEs effectively, particularly if conversion terms are drafted to include biotech-specific milestones as triggers rather than relying solely on a standard priced equity round.
Accelerator-backed biotechs coming through programmes like Y Combinator’s biotech track, IndieBio, or SynBioBeta often issue SAFEs as the default instrument because the accelerator community normalizes them and the investor base understands the mechanics. In those contexts, the SAFE works because both sides know what they’re signing.
When the Conditions Are Right
SAFEs work best in biotech under these specific conditions:
- Your company is pre-IND with a clear 18-24 month path to a priced seed or Series A round
- Your investors are experienced angels or seed funds familiar with SAFE mechanics and biotech timelines
- Your valuation cap reflects genuine IP and data value, not aspirational projections
- You’re raising a single SAFE round, not planning to stack three before a priced event
- Your conversion triggers have been adapted to include biotech-specific milestones
Geographic context matters here. SAFE adoption is higher in US biotech ecosystems. UK and European founders should verify that their target investors, including EIC-backed funds and UK angel networks, are familiar with and willing to accept SAFE terms before defaulting to the Y Combinator template. In the UK, convertible loan notes are more commonly used and may be better understood by the investor base you’re targeting.
Where SAFEs Break Down: Biotech-Specific Failure Modes
The standard SAFE conversion trigger is a “priced round,” meaning a future equity financing above a minimum threshold. Biotech companies frequently receive capital through licensing deals, milestone payments, government grants, or non-dilutive awards that don’t qualify as priced rounds. When that happens, SAFEs sit unconverted, creating investor relations friction and potential legal ambiguity.
What happens to a SAFE note if a biotech company raises a grant instead of equity? Under standard SAFE terms, nothing. The SAFE doesn’t convert. The investor holds an unconverted instrument with no guaranteed return timeline and no governance rights. This is a manageable situation if investors understood it at signing. It becomes a dispute if they didn’t.
Milestone Review Checklist: Before issuing a SAFE, map your anticipated funding milestones against standard SAFE conversion triggers. Identify whether your next major financing event, whether an IND filing, a licensing term sheet, or a strategic partnership, qualifies as a priced equity round under the instrument’s definition. If it doesn’t, negotiate amended conversion language before signing.
The Timeline Mismatch Problem
Biotech development timelines routinely extend 5-10 years before a Series A or IPO. SAFEs have no maturity date, which means investors can hold an unconverted instrument for years without recourse. This is structurally different from a convertible note, which carries a maturity date that creates a defined decision point for both parties.
Sophisticated biotech investors, including corporate VCs, specialist life science funds, and family offices with healthcare mandates, often prefer convertible notes with defined terms or direct equity because these instruments provide clearer governance rights and downside protection. If your target investors fall into this category, presenting a SAFE may signal a mismatch in instrument expectations before negotiations even begin.
Regulatory milestones like IND approval, orphan drug designation, or CE marking can dramatically shift company value between SAFE issuance and conversion. Standard SAFE terms don’t account for these inflection points. A cap set at $4M for a preclinical platform may look punitive at Series A if the company has generated Phase I proof-of-concept data in the intervening period. That misalignment doesn’t resolve itself automatically — it becomes a negotiation problem at the worst possible moment.
SAFE vs Convertible Note vs Priced Round: Choosing the Right Instrument
The decision between a SAFE, a convertible note, and a priced seed round comes down to three variables: your timeline to a priced round, your investors’ expectations, and how much valuation certainty you have right now.
| Instrument | Interest Rate | Maturity Date | Conversion Trigger | Best For |
|---|---|---|---|---|
| Post-Money SAFE | None | None | Priced equity round | 18-24 month path to Series A |
| Convertible Note | 5-8% p.a. | 18-24 months | Priced round or maturity | Uncertain but bounded timeline |
| Priced Seed Round | N/A | N/A | Immediate equity issuance | Sufficient data to defend valuation |
| MFN SAFE | None | None | Priced round (best terms) | Very early stage, uncertain cap |
Convertible notes carry interest, typically 5-8% per annum, and a maturity date, usually 18-24 months. This creates a repayment obligation if conversion doesn’t occur — a meaningful risk for capital-intensive biotech companies with uncertain timelines. Priced seed rounds require agreeing on a company valuation now, which is difficult for preclinical biotechs, but they provide clean cap table mechanics and clear investor rights from day one.
For UK and European founders: Innovate UK Smart Grants and EIC Accelerator grants are non-dilutive and don’t interact with SAFE conversion triggers. Pursue these in parallel with SAFE or convertible note financing rather than treating them as alternatives. An SBIR-equivalent grant in the US context serves the same function. Non-dilutive capital at the preclinical stage is almost always preferable to any dilutive instrument, SAFE or otherwise.
Negotiating SAFE Terms for a Biotech Company
The valuation cap is the single most consequential term in your SAFE negotiation. Set it at a level that reflects your current IP position — filed patents, platform data, a research collaboration — not your aspirational Series A valuation. A cap that’s too low creates significant dilution at conversion. A cap that’s too high deters investors who can’t justify the entry price against your current data package.
Discount Rate and MFN Mechanics
A 15-20% discount to the Series A price is standard. In biotech, where the gap between seed and Series A can span years and multiple data inflection points, consider whether a discount alone, without a cap, adequately compensates early investors for the risk they’re taking. The Most Favoured Nation (MFN) clause is a related consideration: if you issue multiple SAFEs, an MFN clause allows earlier investors to adopt more favorable terms from later SAFEs. Understand how this interacts with your cap table before agreeing to it, because it can create unexpected obligations when later rounds price at different caps.
Conversion Triggers and Pro-Rata Rights
Negotiate to include biotech-specific events as conversion triggers. Licensing deals above a defined threshold, strategic partnerships, or milestone payments can all be drafted as qualifying conversion events if you anticipate these before a priced equity round. This protects both you and your investors from the legal limbo of an unconverted SAFE sitting on the cap table while the company reaches meaningful commercial milestones.
Pro-rata rights, which give investors the right to participate in future rounds to maintain their ownership percentage, are reasonable for lead investors but should be limited to avoid cap table complexity at Series A. Institutional investors at Series A will scrutinize your cap table carefully. A clean structure with defined rights is easier to close than one with multiple overlapping pro-rata obligations.
Practical Steps Before You Issue a SAFE Note
Model your cap table across three scenarios before signing anything: a single SAFE round, two stacked SAFE rounds, and three stacked SAFE rounds. Use post-money dilution mechanics and include a projected option pool expansion in each scenario. This takes a few hours with a spreadsheet and saves you from an unpleasant conversation with your co-founders eighteen months later.
- Confirm that your target investors understand and accept SAFE instruments — in UK and European markets, some investors are unfamiliar with the structure and may require a convertible note or equity alternative
- Engage a specialist life sciences lawyer to review SAFE terms before signing — standard Y Combinator SAFE templates are US-law documents and require adaptation for UK or EU jurisdiction, particularly around conversion mechanics and investor rights
- Align your valuation cap with your IP position: filed patents, platform data, and research collaborations should anchor your cap negotiation rather than comparable company multiples
- Identify the specific milestone that will trigger your Series A process — IND filing, Phase I data readout, licensing term sheet — and communicate this to SAFE investors at the time of signing
- Review whether any anticipated non-dilutive funding events, including grants or government awards, could be misinterpreted as conversion triggers or create confusion about company valuation
Share your SAFE terms with your legal counsel before drafting investor documents, and ask them to flag any clauses that don’t translate cleanly into your jurisdiction. A US SAFE template used in a UK company without adaptation can create ambiguity around shareholder rights, dissolution provisions, and conversion mechanics that becomes expensive to resolve later.
FAQ: SAFE Notes in Biotech
Can a SAFE note be used before an IND filing?
Yes, a SAFE can be issued at any stage, including pre-IND. The question is whether the terms reflect your current risk profile accurately. Pre-IND biotechs have limited data to anchor a valuation cap, which makes cap negotiation speculative. If you’re pre-IND, consider whether a SAFE with a conservative cap, a convertible note, or non-dilutive grant funding better fits your stage and investor expectations.
What happens to a SAFE note if a biotech company raises a grant instead of equity?
Under standard SAFE terms, a grant award doesn’t trigger conversion. The SAFE remains outstanding and unconverted. This is legally clean but creates investor relations pressure if the grant is substantial and the company’s value has increased materially. If you anticipate significant grant funding, negotiate amended conversion language that addresses this scenario explicitly before issuing the SAFE.
How does a SAFE note convert in a Series A round?
When a company closes a priced Series A round, the SAFE converts into the same class of equity being issued in that round, at either the capped price or the discounted price, whichever gives the SAFE investor more shares. In a post-money SAFE, the investor’s ownership percentage at conversion is determined by dividing their investment by the post-money valuation cap. The conversion is automatic and simultaneous with the Series A close.
When should a biotech startup use a SAFE instead of a convertible note?
Use a SAFE when you have a clear 18-24 month path to a priced institutional round and your investors are comfortable with the instrument. Use a convertible note when your timeline is uncertain but bounded, when investors require a maturity backstop, or when your target investors, particularly in European markets, are more familiar with debt-based instruments. The absence of interest and a maturity date makes SAFEs simpler, but that simplicity only benefits you if conversion happens on a predictable schedule.
What valuation cap is appropriate for a preclinical biotech?
There’s no universal answer, but a defensible cap reflects your IP position, not your aspirational exit value. If you have filed patents and platform data, these assets anchor the negotiation. If you have a research collaboration or a named academic partner, that adds credibility to a higher cap. Preclinical biotechs without clinical data should be cautious about setting caps that imply valuations their data can’t support, as this creates friction at Series A when institutional investors price the round independently.
Do post-money SAFEs protect founders from dilution?
Post-money SAFEs provide clarity about dilution, not protection from it. The structure makes the dilution calculation predictable rather than ambiguous. Whether that dilution is acceptable depends on the cap you negotiate and how many SAFEs you stack before a priced round. The 85% adoption rate of post-money SAFEs reflects investor preference for clarity, not founder preference for favorable terms.
Your next step: Run a three-scenario cap table model using the stacking mechanics described in this guide, then review your anticipated funding milestones against standard SAFE conversion triggers. If your next major financing event doesn’t qualify as a priced equity round under a standard SAFE template, negotiate amended conversion language before you sign. The instrument is flexible enough to accommodate biotech realities — but only if you build those realities into the terms from the start.
- SAFE Notes in Biotech: When They Work and When They Don’t - June 8, 2026
- Thyroid Eye Disease and Sinus Problems: Understanding the Connection and Treatment Options - April 19, 2026
- Best Payment Hubs for Banks and Financial Institutions in 2026: Compliance, Innovation, and Real-Time Readiness - March 24, 2026